SAB Biotherapeutics, Inc. 8-K

What Happened
SAB Biotherapeutics, Inc. (SABS) filed an 8‑K on March 19, 2026 disclosing an underwritten public offering. On March 17, 2026 the company entered into an underwriting agreement with Jefferies, UBS, Citigroup and Barclays as representatives for the underwriters to sell: 19,324,677 shares of common stock at $3.85 per share and pre‑funded warrants to purchase up to 2,753,246 shares at $3.8499 per warrant (the $3.8499 price reflects a $0.0001 per‑share exercise price). The offering may include an additional 3,311,688 optional shares if the underwriters exercise a 30‑day option. The offering is expected to close on March 19, 2026.

Key Details

• Offering size: 19,324,677 Firm Shares + up to 2,753,246 Pre‑Funded Warrants; 30‑day option for an additional 3,311,688 shares.
• Public prices: $3.85 per common share; $3.8499 per pre‑funded warrant (exercise price $0.0001).
• Estimated net proceeds: approximately $69.7 million (or ~$81.7 million if the underwriters buy the optional shares), after fees and expenses, assuming no exercise of the Pre‑Funded Warrants.
• Underwriters/representatives: Jefferies LLC, UBS Securities LLC, Citigroup Capital Markets, Inc. and Barclays Capital Inc.; securities issued under a Form S‑3 shelf registration effective Jan 7, 2026.

Why It Matters
This filing signals a near‑term capital raise intended to provide the company with additional liquidity—about $69.7M before optional share sales—by issuing new shares and pre‑funded warrants. For investors, this issuance can dilute existing shareholders if and when the warrants are exercised and if the optional shares are purchased; it also increases the potential share overhang until the offering and any warrant exercises are completed. Monitor the closing (expected March 19, 2026), whether the underwriters exercise their option, and any future filings disclosing use of proceeds.